---
title: 'Director, Business Development at Triveni Bio'
canonical: 'https://feeny.ai/job/director-business-development-triveni-bio-watertown-f4sers3555gh'
type: 'job'
last_seen: '2026-09-12'
---

# Director, Business Development at Triveni Bio

- **Company:** Triveni Bio
- **Location:** Watertown, MA
- **Compensation:** $220k–$240k
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-07-17
- **Last confirmed live:** 2026-09-12
- **Apply:** https://jobs.lever.co/trivenibio/a291dd1d-2684-47fe-b1bf-b25ed7ed9d08

## Job description

## COMPANY INTRODUCTION

Triveni Bio is breaking new ground in the identification of novel disease targets – working at the convergence of human genetics, best-in-class antibody design, and precision medicine.  We are pioneering a Mendelian genetics-informed precision medicine approach to develop functional antibodies for the treatment of immunological and inflammatory (I&I) disorders. Our lead antibody program (TRIV-509) targets kallikreins 5 and 7 (KLK5/7) to directly impact skin barrier function, inflammation, and itch – providing a meaningful and much needed potential treatment option for patients with atopic dermatitis and other barrier disorders. In all the work we do, we adhere to our core values: patient impact, bold and rigorous science, open collaboration, kindness & respect.

## SUMMARY

As Director, Business Development, you will execute Triveni Bio’s external innovation and partnering strategy to expand our pipeline and maximize the value of our platform. Reporting to the COO, you will be responsible for identifying, evaluating, negotiating, and closing strategic transactions including in-licensing, out-licensing, collaborations, and strategic partnerships.  On a day-to-day basis, you will proactively source opportunities aligned with Triveni’s focus in immunology and inflammation, conduct scientific and commercial assessments, build financial models, and drive cross-functional diligence efforts. You will work closely with Research, Clinical, Corporate Strategy, Legal, Finance and Executive Leadership to advance transactions from initial outreach through deal execution. As part of a lean and highly collaborative team, you will gain exposure to enterprise strategy, portfolio prioritization, and executive decision-making, while directly influencing the growth trajectory of the company.  This position requires a blend of deep scientific fluency and advanced transactional acumen.

## RESPONSIBILITIES

Search & Evaluation: Identify and proactively evaluate external opportunities including in-licensing, out-licensing, partnerships, and collaborations aligned with Triveni’s strategyBuild and maintain a robust external network across biotech, pharma, academia, and investorsCollaborate closely with Corporate Strategy to monitor industry trends, competitive landscape, and emerging technologies to inform business development strategyCompile comparable transactions, develop financial models and generate valuation analyses to support deal structures and investment decisions and strategic priorities and trade-offs Diligence Leadership: Partner cross-functionally (R&D, Clinical, Regulatory, Legal, Finance, etc.) to manage diligence processes and align stakeholders Manage technical and corporate virtual data room to ensure stage-appropriate disclosures Lead all external diligence processes (FAQs, Q&As, etc.) Deal Execution: Work closely with COO and Legal to participate in end-to-end deal execution including drafting, structuring and negotiation of complex term sheets and definitive agreements Act as business for normal course BD contracting (e.g., tech transfer, MSAs, SRA, etc.) Alliance Management: Support alliance management activities for existing partnerships Competitive intelligence: Monitor industry trends, competitive dynamics, and emerging opportunities to inform corporate strategy Integrate AI to automate and disseminate information on key updates in near real time Other duties as assigned

## EXPERIENCE & QUALIFICATIONS

Bachelor’s degree in life sciences, business, or related field; advanced degree (PhD, MD, MBA) preferred 8+ years of business development, corporate development, or related experience within a biotechnology or pharmaceutical company Demonstrated track record of successfully leading and closing multiple business development transactions (e.g., licensing, partnerships, or M&A deals) in the biotech/pharma industry Strong experience conducting scientific and commercial diligence and building valuation/financial models Experience working cross-functionally with research, clinical, and G&A teams to execute complex deals Ability to travel up to 20–30% as needed for partner meetings, conferences, and industry events

The posted range reflects the current reasonable and good faith estimate of the base salary for this full-time position. Actual compensation will be based on a variety of factors including, but not limited to, relevant skills and experience, educational background and certifications, performance and qualifications, market demand for the role, geographic location and other organizational needs. This role also offers a competitive target bonus, equity, and a comprehensive benefits package.

We are committed to fair pay practices, and we regularly review our compensation programs to ensure they are competitive, equitable, and aligned with our values. Please note that the advertised pay range is not a guarantee or promise of a specific wage.

Triveni Bio, along with other biotech companies, has become aware of a surge in email scams targeting prospective job candidates within our industry. Official Triveni Bio applications will always be submitted through Lever, our ATS. Any applications that take you to other platforms could be fraudulent. We do not use text or chat applications to conduct interviews or make job offers. Official Triveni Bio correspondence will always be conducted from email addresses ending in @triveni.bio or @hire.lever.co. Please disregard any other communications that do not originate from these domain names. If you receive any suspicious requests or communications, please verify their authenticity before responding.

## About Triveni Bio

## Company Overview
- **One-liner**: Triveni Bio is a clinical-stage biotechnology company applying a genetics-informed precision medicine approach to develop functional antibodies for immune and inflammatory (I&I) disorders.
- **Entity Type**: Private (Series C; total funding $223.4M)
- **Headquarters**: Watertown, Massachusetts, United States
- **Founded**: Not publicly available (earliest funding round was Series A in 2020)
- **Founders**: Not publicly available (key leadership includes CEO Vishal Patel, CSO Jennifer Dovey [founding employee], CMO Bhaskar Srivastava, COO Nicholas Scarchilli)

## Core Business
- Primary industry: Biotechnology (therapeutics for inflammatory and immune-mediated diseases)
- Target customers: Patients with I&I disorders, physicians, and pharmaceutical partners (B2B + B2C model)
- Mission statement: "Our measure of success is the impact we have on patients."

## Products & Services
- **TRIV-509** – A first-in-class, dual-specific, half-life extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7). Currently in Phase 2 clinical trials for moderate-to-severe atopic dermatitis, with potential expansion into eosinophilic esophagitis (EoE) and epidermal differentiation disorders (EDD). (Therapeutic antibody – biologic)
- **TRIV-573** – A second-generation bispecific antibody combining dual inhibition of KLK5/7 with an anti-IL‑13 mechanism. Currently in Phase 1, with plans to initiate a Phase 2 proof-of-concept trial in moderate-to-severe atopic dermatitis in the second half of 2026. (Therapeutic antibody – bispecific)
- **TRIV-920** – A first-in-class monoclonal antibody targeting trypsin 1 and 2 for the treatment of pancreatitis (preclinical stage). (Therapeutic antibody – first-in-class)

## Market Standing
- **Valuation**: Not disclosed
- **Key Metric**: Total funding of $223.4M (3 rounds: Series A $16.4M in 2020, Series A‑2 $92M in 2023, Series B $115M in 2024, and an undisclosed Series C led by Janus Henderson Investors and Ascenta Capital in 2026)
- **Notable Investors/Partners**: Atlas Venture, Cormorant Asset Management, Goldman Sachs Alternatives, Janus Henderson Investors, Ascenta Capital
- **Growth Signals**: 43.6% year-over-year headcount growth (now 47 employees); expanded into new headquarters in Watertown, MA; advanced TRIV‑509 into Phase 2; initiated first human studies for TRIV‑573; raised Series C to broaden clinical studies and drive company growth.

## Competitive Advantages
- **Genetics‑informed target selection**: Uses integrated multi‑omic datasets and “knowledge graphs” to identify disease drivers (e.g., KLK5/7 in atopic dermatitis) and leverage both risk and protective alleles.
- **Advanced antibody engineering**: Developed a single monoclonal antibody that binds both KLK5 and KLK7 with equal potency, overcomes historic targeting challenges, and includes half‑life extension for convenient dosing.
- **First‑in‑class potential**: TRIV‑920 addresses pancreatitis, a condition with no approved therapies, showing preclinical reduction of pancreatic damage markers.

## Strategic Focus
- Advance TRIV‑573 through Phase 2 proof‑of‑concept in atopic dermatitis (2H 2026).
- Expand TRIV‑509 into additional indications (EoE, EDD).
- Continue preclinical development of TRIV‑920 for pancreatitis.
- Scale the organization while maintaining a collaborative, patient‑focused culture.

## Why Work Here
- **Culture**: Described as “bold & rigorous,” collaborative, and kind, with a strong emphasis on patient impact. Employees note that leadership actively listens and creates a safe space for ideas.
- **Location**: On-site in Watertown, MA (newly expanded headquarters) with an additional office in Waltham.
- **Work Environment**: Clinical‑stage biotech with exciting science; opportunity to “make medicines for patients in need alongside colleagues pushing the boundaries of science and medicine.”
- **Perks**: Not explicitly detailed, but the organization values “curious minds” and “drive to turn ideas into impact.”

## Sources
1. [triveni.bio/about](https://triveni.bio/about/)
2. [triveni.bio/pipeline](https://triveni.bio/pipeline/)
3. [triveni.bio/science](https://triveni.bio/science/)
4. [linkedin.com/company/triveni-bio](https://linkedin.com/company/triveni-bio)
5. [jobs.lever.co/trivenibio](https://jobs.lever.co/trivenibio)

## Other roles at Triveni Bio

- [Director, AI and Data Science](https://feeny.ai/job/director-ai-and-data-science-triveni-bio-watertown-hny7b1d8bar4) — Watertown, MA
- [Director, Business Development](https://feeny.ai/job/director-business-development-blitzy-cambridge-19b0p3dke4ep) — Cambridge, MA
- [Director, Business Development](https://feeny.ai/job/director-business-development-dailypay-new-york-kfjwdznw3r9m) — New York, NY
- [Director, Business Development](https://feeny.ai/job/director-business-development-everway-albertslund-zfn7n1ny09kx) — Albertslund, Denmark
- [Director, Business Development](https://feeny.ai/job/director-business-development-chownow-canada-t4nqwaf2x0pz) — Canada
- [Director, Business Development](https://feeny.ai/job/director-business-development-radar-new-york-phrsa2d95kr5) — New York, NY
- [Director, Business Development](https://feeny.ai/job/director-business-development-inovalon-tampa-ykfcy9f1wgp5) — Tampa, FL
- [Director, Business Development](https://feeny.ai/job/director-business-development-chownow-remote-q25jnrvhnvck)
- [Director, Business Development](https://feeny.ai/job/director-business-development-code-and-theory-new-york-new-york-g22y61wyxn05) — New York New York, United States
- [Director, Business Development](https://feeny.ai/job/director-business-development-schrodinger-cambridge-26j7efm0r9fr) — Cambridge, MA / New York, NY